Not yet recruitingPhase 1

A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight

An Investigation of the Effect of High Dose s.c. Semaglutide on Gastric Emptying in Participants With Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI 30-44.9

Primary endpoint

•AUC of paracetamol following a standardised meal

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07845578

Org study IDNN9536-8797

Secondary ID2026-526083-20European Medical Agency (EMA)

Secondary IDU1111-1335-9563World Health Organization (WHO)

Timeline

Milestones

Study start2026-09-25estimated

Study first posted2026-09-29actual

Last update posted2026-09-29actual

Primary completion2027-09-11estimated

Study completion2027-09-11estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age64 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age 18-64 years (both inclusive) at the time of signing the informed consent.

•Male or female (sex assigned at birth, inclusive of all gender identities).

•Body mass index (BMI) between 30.0 - 44.9 kilogram per meter square (kg/m^2) (both inclusive) at screening. Obesity should be due to excess adipose tissue, as judged by the investigator.

Exclusion criteria

•Known or suspected hypersensitivity to study intervention(s) (including paracetamol) or related products.

•Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval) and occasional use of paracetamol/acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.

•Impaired liver function defined as any of the below:

1. Alanine Aminotransferase (ALT) greater than or equal to (>= ) 2.5 times the upper limit of normal (ULN)

2. Aspartate Aminotransferase (AST) >=2.5 times ULN

3. Total bilirubin greater than (>) 1.5 times ULN

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints

Primary/protocol endpoint

AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal

Time frame:Day 177

concentration, descriptive

Secondary/protocol endpoint

AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal

Time frame:Day 177

concentration, descriptive

Secondary/protocol endpoint

Cmax,para; Maximum observed paracetamol plasma concentration following a standardised meal

Time frame:Day 177

concentration, descriptive

Secondary/protocol endpoint

tmax;para: Time to maximum observed paracetamol plasma concentration

Time frame:Day 177

time to event, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.